Connect with us

Biotechnology

Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks

Joe Samuel

Published

on

If you’ve ever invested in the stock market or traded a single share, chances are you’ve familiarized yourself with the “hot markets”. These are the ones that consistently see enormous volatility and gains that most only dream of.

More times than not, biotechnology and healthcare stocks are the “hot markets” and we’ll explain exactly why. We’ll also take a deep dive into a niche that you must be paying attention to in 2019 if you’re looking to take advantage of the next big trend in health science.

Biotech Companies Are Driving Innovation

Why biotech over other sectors? Two words: Life Changing.  Sure the latest iPhone or newest gadget may be a “life-changing” product to make your life more exciting but in this hot market, we’re literally talking life-changing and life-saving bi-products. 

Think about what would happen to a stock if a company were to find a cure for cancer? Better yet, what would happen if a company found a solution for HIV?

We’ll talk more about these topics but the simple fact of the matter is that companies are dumping billions of dollars into this sector to take advantage of the next trillion-dollar idea. One place, in particular, is in cancer-fighting stocks.

Cancer Fighting Stocks Are Getting Gobbled Up

The global market for cancer drugs is estimated to be about $123 billion and big players are investing heavily to gain an edge in this increasingly competitive market[1].  Pharmaceutical giant Bristol-Myers, a pioneer in immunotherapy, is acquiring rival Celgene for $74 billion.

Merck is acquiring cancer drug developer Peloton Therapeutics for $1.05 billion. The announcement came as Peloton was preparing for its IPO.  Earlier this year, Eli Lilly bought Loxo Oncology for $8 billion. And this is just the tip of the iceberg for cancer-fighting stocks!

Where Will The Focus Be Next? Read Between The Lines

According to people like Brad Loncar, CEO of Loncar Investments, companies at the forefront of immunotherapy research is the place to be. He’s focused on the important developments in the space and promising work being done by some smaller, innovative biotech companies.

We may have just uncovered a company set to take the stage in immunotherapy.

One of the top holdings of Loncar’s Cancer Immunotherapy ETF [2] is Iovance Biotherapeutics (formerly Lion Biotechnologies).

Why’s this important?

The reason isn’t so much about “why” but about “who.” Founder and previous CEO of Iovance Biotherapeutics, Anthony Cataldo was able to grow Iovance early on, and the company currently holds a market cap of over $2 billion with a share price above $17 per share.

This is key because Mr. Cataldo has recently taken the helm of one “small” immuno-oncology company focused on novel therapies, GT Biopharma (GTBP), which may signal the next big opportunity in biotech.

GT Biopharma (GTBP) is under his direct control and the best part is that this isn’t just a story about a biotech industry leader building the next market disruptor. The pipeline that GT Biopharma (GTBP) has amassed could be on the verge of something big.

GT Biopharma (GTBP)’s Next Move

Early, clinical stage companies like GT Biopharma (GTBP) present a number of value propositions for investors.  Though many of these companies can hold higher risk due to lack of revenues, incurring high levels of expenses due to research, development, and SG&A, they can also offer higher rewards if early successes are realized.

So far, GT Biopharma has come up favorably with respect to trial results on more than just one of its therapies in the pipeline.  Certainly, though the most recent developments with it OXS-1550 could deliver the most near term opportunities.

The company’s previous announcement that it would be working with a “major pharmaceutical company” may suggest that GT Biopharma (GTBP) could be positioning itself for a strategic move at the very least. 

Though the “major company” was left nameless, we can infer from comments made by Dr. Daniel Vallera that the “multi-billion dollar oncology drug” is ibrutinib. The statement made in a company press release specifically stated, “We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib, a potent small molecule Bruton Tyrosine Kinase (BTK) inhibitor which is already an established chemotherapeutic agent.  We believe combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment.”

Knowing this, we can begin connecting dots to the companies linked to ibrutinib. Its trade name is Imbruvica and is a drug that was developed by Pharmacyclics and Janssen. 

Both Pharmacyclics and Janssen are subsidiaries of major pharmaceutical companies; Abbvie and Johnson & Johnson respectively.

Ibrutinib has already shown efficacy with other combination therapies like Venetoclax (marketed by Abbvie & Genentech) as well as Rituxan (rituximab), currently co-marketed by Biogen and Genentech in the U.S., for the treatment[3] of patients with a rare type of non-Hodgkin’s lymphoma called Waldenström’s macroglobulinemia.  The U.S. Food and Drug Administration recently approved Imbruvica (ibrutinib) plus Rituxan (rituximab) as a treatment.

That was in August of 2018 and even though this alone might get investors excited about GT Biopharma (GTBP), a lot has happened since then that could really put a spotlight on this company!

GTB-1550 Phase I-II Results Have Opened The Door For Bigger Opportunities

GT Biopharma’s lead treatment, GTB-1550 is a novel multi-target directed therapy for the treatment of chemotherapy-refractory B-cell malignancies, including Non-Hodgkins Lymphoma and Leukemia.

To date, GT Biopharma has completed one dose escalation Phase I-II expansion clinical trial, and one fixed dose Phase I-II expansion clinical trial which collectively enrolled a combined 43 patients. On the surface, the Phase I-II expansion clinical trial demonstrated greater than 50% of Evaluable patients receiving 60 mg/kg dose had a positive clinical response.

Top-line Consolidated Results:

  • Two patients exhibited a Complete Remission (CR) with one patient currently disease-free at 50 months post-treatment.
  • Five patients exhibited Stable Disease (SD), cancers that are neither increasing or decreasing in severity, with the longest response lasting 12 months post-treatment.
  • Two patients with transformed lymphoma showed transient tumor shrinkage, however, therapy was discontinued due to dose-limiting toxicities after the 1st cycle.
  • Greater than 50% of evaluable patients, (patients where response to treatment can be measured because enough data has been collected), receiving 60 mg/kg dose had positive clinical response defined as stable disease, partial remission, or complete remission.

“GTB-1550 has shown positive results in its two Phase I-II clinical trials in advanced cancer patients who have failed all other therapies, and we are now planning to proceed with a Phase II clinical trial.”

Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma

But this Phase II opportunity is just the “first phase” of GT Biopharma’s potential.  In early April of this year, the company received authorization from the University of Minnesota’s Institutional Review Board and Cancer Protocol Review Committee to proceed with a TriKE Phase 1 clinical trial.

Pipeline Therapies Gain Phase I Trial Approval

The study on its GTB-3550 will enroll up to 60 subjects and will be led by Principal Investigator, Erica Warlick, MD. Warlick is Associate Professor of Medicine, Division of Hematology, Oncology, and Transplantation at Masonic Cancer Center, University of Minnesota.

Specifically, the company will be looking for favorable results on the treatment of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and mastocytosis.

And just as with its GTB-1550, GTB-3550 addresses a specific group of patients.  AML is the most common form of adult leukemia with 21,000 new cases expected in 2018 alone, according to the American Cancer Society. AML patients typically receive frontline therapy, most commonly chemotherapy, which includes cytarabine and an anthracycline, a therapy that has not changed in over 40 years. 

When it comes to other things like MDS, the number of people with MDS diagnosed in the U.S. each year is estimated to be ~10,000 and can progress to AML. Mastocytosis is rarer. An estimate of prevalence from a recent population-based study is approximately 1 case per 10,000 people.

GTB-3550 is being developed to serve as a relatively safe, cost-effective, and easy-to-use therapy for resistant/relapsing AML. It could also be combined with chemotherapy as frontline therapy, thus targeting the broader patient population.

New Findings Suggest GT Biopharma Therapies May Eliminate HIV Infected Cells

It’s a regular occurrence but one that isn’t generally covered with certain biotech companies. But with certain therapies, there can be additional applications.  Most of the time they are less impactful than the target endpoints.  In the case of GT Biopharma (GTBP) its Tri-Specific Killer Engager may have a massive opportunity after recent findings!

The company’s therapy showed that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could actually be eliminated!

We talked about it at the beginning of this report – Why biotech over other sectors? Two words: Life Changing – and this could be one of those “life changing” moments to pay very close attention to.

GT’s products will need to continue to produce positive results in order for investors to remain interested. And this having been said, indications have already been in motion giving even more legitimacy to GT Biopharma’s platform.

Case and point: would it be out of the question for GT Biopharma to obtain a strategic investment similar to the Affimed/Genentech deal? In our opinion, it wouldn’t be out of the question at all; here’s why:

Standing Toe To Toe With Industry Heavyweights

Both platforms utilize fusion proteins with one end binding to NK cells and the other targeting a tumor antigen however there are still a number of differences in the platforms.  Many of these differences are based on exactly how the proteins are created and how they face the NK activation and proliferation issues.

Essentially, without a specific stimulatory agent, the cells become exhausted as their numbers decline. Specifically, GT Biopharma’s NK cell-engager platform incorporates Interleukin (IL)-15. No other, including Affimed’s, NK cell technology has this.

From other research done on NK cells, it has been found that boosting NK cell numbers [4] by treating them with IL-15 may be a valuable new approach to increasing our immunity to viral infections or cancer. IL-15 is a growth factor for certain kinds of white blood cells, including natural killer cells and T cells.

GT Biopharma’s TriKE (Tri-specific Killer Engager) technology has shown superior NK cell cytotoxicity against hematologic tumors in preclinical work compared to earlier versions of the drug. TriKEs are an off the shelf option that employ a single chain, tri-specific fusion protein that binds to CD16 on NK cells and targets tumor antigens on cancer cells such CD33 in myeloid malignancies.

TriKEs are particularly attractive due to their low cost of manufacture relative to CAR-T therapy and can be used off the shelf without any modifications of autologous cells in the lab. The company is currently in the process of submitting an investigational new drug application to the FDA for the TriKE in order to launch a Phase I/II trial in the second half of this year.

This, in addition to several other key therapies in the company’s pipeline could bode as attractive targets for larger investment from the likes of major pharmaceutical companies.

At The Forefront of the Cancer Wars & Ready To Deliver

Medical science hasn’t yet won the war on cancer, but it is scoring important victories in battles against many forms of the disease. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks.

It isn’t just small family offices taking a shot at this arena anymore. Major industry leaders are taking every chance they can at buying up smaller companies before they become the direct competition. The figures are becoming even more staggering as new therapies and phase trials materialize. GT Biopharma (GTBP) can make a convincing argument to become one of the top biotech stocks to watch.

“Big Pharma appreciates innovation and respects how it happens. That’s why the industry is interested in doing great deals with young companies that can move fast to solve big scientific problems.”

Abbie Celniker, Ph.D., partner at Third Rock Ventures.

The health sciences market is experiencing unprecedented innovation, and now the race is to get behind the next breakthrough. GT Biopharma’s numerous phase trials, novel treatments, and top tier leadership are just some of the main topics to consider in our opinion.

In the end, this company is in early to mid-phase trials with proven results and has even shown indications for other immune-therapies to the extent that it has eliminated infected targets. With all of the activity going on within the immune-therapy space as it is, can you afford not to be paying attention right now?

biotech stock to buy 2019
Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Endnotes:

[1]Brad Loncar -https:// finance. yahoo. com /news/why-cancer-fighting-stocks-etfs-184606099. html

[2]Loncar ETF Info – https:// etfdb . com /etf/CNCR/

[3] https:// lymphomanewstoday . com /lymphoma-treatment/

[4] NK Cell cancer immunity – https:// medicalxpress .com /news/2017-01-natural-killer-cells-cancer-immunity. html

Continue Reading
1 Comment

Biotechnology

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

Joe Samuel

Published

on

stock market today

Biotech has been one of the hottest sectors for investors for as long as it has existed and the reasons are self-evident. It is a sector that uses cutting edge technology and comes up with treatments for a wide range of diseases.

Moreover, the fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 19, PharmaCyte saw more than 6 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

What To Watch For

This week PharmaCyte (PMCB) will host a call designed to update all shareholders and the investment community simultaneously of material developments. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. FDA to treat locally advanced, inoperable pancreatic cancer. It will also cover developments related to PharmaCyte’s product pipeline. PharmaCyte has been working on these and will discuss things not yet reported in a press release.

Catalyst Pharmaceuticals (CPRX)

The first one to watch is Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). It is a small-cap stock engaged in developing medicines for rare diseases. Catalyst managed to get an approval for one of its products from the FDA earlier this year.

Since the approval of the Lambert-Eaton myasthenic syndrome (LEMS treating medicine Firdapse, Catalyst stock went on a massive rally from January to April. The approval of a rival drug halted the rally. Only after a civil suit from Catalyst did the stock stabilize somewhat.

Last week, Catalyst stock received a fresh boost after the company announced that it was going to make a secondary offering. However, the company decided to pull the offering the very next day and that affected the stock price once again.

What To Watch For

Analysts believe that pulling the secondary offering was the right long term decisions and this stock could be heading for another rally soon.

Eyepoint Pharmaceuticals (EYPT)

The biotech stock that could prove to be a major winner in the biotech sector this month is that of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT). There are two factors at play. The company revenues are going to rise significantly in the coming years due to the commercial launch of two medicines.

The first one is Yutiq, which is meant for the treatment of chronic non-infectious uveitis and the other one is Dexycu, which is meant for postoperative ocular inflammation.

What To Watch For

The company is currently trading at only double that of its future revenue and that is a very attractive multiple. EYPT stock has caught the attention of analysts on Wall Street. Guggenheim has set a 12-month target price of $4, which reflects 116% gains during the period.

stock market news today
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Biotechnology

Acadia (ACAD) Stock Price is up 60% This Month; Bullish Signal For Biotechs?

Joe Samuel

Published

on

One sector that has always been a favorite of investors of all varieties is the pharmaceutical sector and all investors like a turnaround story. Over the years, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had been one of the better-known strugglers in the industry. That was reflected in the stock price as well. But recent developments have breathed new life in the stock, which could be an indicator for the biotech industry at large.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.

Acadia (ACAD) Stock Price: Important Developments

People who had held on to the stock through the barren years got a nice boost recently. This came after Acadia’s well-known medicine Nuplazid recorded better than expected sales. In addition to that, there were encouraging results from a dementia-driven psychosis study. Hence, it is important to figure out whether it is perhaps time to buy the stock.

While the signs are no doubt encouraging, it is important to note that data reveals that around 60,000 people in the United States are diagnosed with Parkinson’s every year. Out of those, a large proportion (50% to 80%) suffers from dementia. Hence it can be argued that the market is simply not too big for Acadia’s Nuplazid.

Moreover, different types of dementia are brought on by Alzheimer’s disease, which is why all of it might not actually fall into Acadia’s lap. That being said, it is also well known that antipsychotic drugs have only been approved for the treatment of Parkinson’s and hence the Alzheimer’s market is already out of the question.

Market Potential

Projections suggest that the sale of Nuplazid could grow to more than $1 billion in 2023 from $224 million in 2018. While that is encouraging, it is also important to note that the growth has been priced into the Acadia stock price.

However, if Acadia’s plans for growth somehow run into any trouble, then there is every chance of the stock price plummeting once again. The company is recovering and there is some time before the patient population for Nuplazid can be expanded sufficiently. In the meantime, investors need to be a bit more patient.

Shares of ACAD are up over 60% over the past week and made a new multi-year high of $43.98.

biotech stock price
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Biotechnology

Top Biotech Stocks To Watch This Week

Joe Samuel

Published

on

best biotech stocks to watch

Biotech stocks rarely perform well during the summer months, and 2019 has proven to be no exception in regards to this historical pattern. The iShares Nasdaq Biotechnology ETF, for example, has fallen by nearly 2% since the official start of summer.

The values of biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is that the latter part of the year is chock-full of key data readouts, regulatory decisions, and thousands of scientific conferences across the globe. 

Biotech Stocks To Watch

GT Biopharma (GTBP)

Earlier this quarter GT Biopharma, Inc. (GTBP) an immuno-oncology company focused on innovative treatments based on the Company’s proprietary NK cell engager announced that Jeffrey Miller, M.D. has been hired by the Company as its Consulting Chief Medical Officer.

Further to this, the company confirmed that it had notified FDA that it was commencing enrollment in its first-in-human GTB-3550 Phase I/II clinical trial. The clinical trial is being conducted at the University of Minnesota’s Masonic Cancer Center in Minneapolis, Minnesota under the direction of Dr. Erica Warlick.

GTB-3550 (OXS-3550) is the Company’s first Tri-specific NK cell Engager (TriKE™) product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15.

Since making the announcement, shares of GTBP are up by 13.2%.

NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corp (NASDAQ:NLNK) said the FDA has accepted partner Merck & Co., Inc. (NYSE:MRK)’s BLA for its investigational Ebola vaccine, according to the application priority review status. The PDUFA goal date has been set for March 14, 2020.

Potential approval of the vaccine will trigger issuance of a priority review voucher, owned by Merck and in which NewLink has a substantial economic interest. NewLink can then monetize its share of interest in the voucher. The vaccine candidate, originally developed by the Public Health Agency of Canada, was licensed to NewLink.

vTv Therapeutics Inc (NASDAQ:VTVT)

vTv Therapeutics Inc (NASDAQ:VTVT) is scheduled to present at the European Association for the Study of Diabetes 55th annual meeting being held in Barcelona, Spain with a new Phase 1/2 Simplici-T1 study of liver-selective glucokinase activator TTP399 as an adjunctive treatment for Type 1 diabetes.

Biotech IPO To Watch

IGM Biosciences priced its IPO of 10.938 million shares at $16, the midpoint of the estimated price range of $15-$17 per share. The shared of the preclinical and clinical-stage immuno-oncology biotech will be listed on the Nasdaq under the ticker symbol “IGMS.”

best biotech stocks to watch
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $15,000 per month for 6 months by GT Biopharma (GTBP) for a period from September 4, 2019 to March 4, 2020. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com